DVYSR.ST Devyser Diagnostics AB

Healthcare Biotechnology Stockholm Exchange
64.80 SEK
Close of Nov 7, 2026
48.50 120.00
Market cap
SEK 1.09B
P/E
42.6x
P/B
2.93x
ROE
4.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DVYSR.ST undervalued?

Graham number
Price64.80
Graham value27.50
Premium135.7%

DVYSR.ST trades 135.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Devyser Diagnostics AB fundamental analysis

No fundamental analysis for Devyser Diagnostics AB yet.

Devyser Diagnostics AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Adv…

Full company profile